Trial reportChinese journal of integrative medicine2026
Effect of Taoren Honghua Jian Granule on NLRP3 Inflammasome Expression in Patients with Stable Coronary Artery Disease: A Multi-Center, Double-blind, Randomized Controlled Trial.
Trial report in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy of Taoren Honghua Jian Granule (THJ) in stable coronary artery disease (SCAD) patients with syndrome of qi stagnation and blood stasis, and to investigate its effect on the expression of NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome in peripheral blood mononuclear cells (PBMCs).
methodsIn this multicenter, double-blind, randomized controlled trial, 80 eligible SCAD patients from 3 Shanghai hospitals were randomly assigned to receive either the THJ (18.3 g, twice daily, orally) or a matched placebo for 4 weeks 40 in each group, followed by a 4-week follow-up. Chinese medicine (CM) Syndrome Scores and Seattle Angina Questionnaire (SAQ) assessments were conducted pre- and post-intervention. Quantitative PCR was used to analyze mRNA levels of NLRP3 inflammasome components [NLRP3, apoptosis-associated speck-like protein (ASC), caspase-1, interleukin (IL)-1β, and IL-18] in PBMCs, while ELISA was used to detect plasma inflammatory cytokines [IL-10, IL-1β, IL-2, IL-6, IL-8, IL-18, tumor necrosis factor (TNF-α), and high-sensitive C-reactive protein (hs-CRP)].
resultsAfter 4 weeks of treatment, the overall treatment efficacy was higher in the treatment group than in the placebo group; the CM syndrome scores of the two groups were significantly lower after treatment, and the THJ group was considerably lower than the placebo group (P<0.05, P<0.01). The THJ group had significantly higher scores for 5 SAQ dimensions than the placebo group (P<0.01). Both mRNA expression of NLRP3 inflammasome components (NLRP3, ASC, caspase-1, IL-1β, IL-18) decreased in PBMCs (P<0.01). In addition, plasma levels of IL-2, IL-8, IL-18, and TNF-α significantly decreased in THJ group compared with the placebo group after treatment (P<0.05, P<0.01).
conclusionsTHJ alleviates angina symptoms and improves quality of life in SCAD patients, potentially through NLRP3 inflammasome inhibition and subsequent attenuation of pro-inflammatory cytokine release. These findings position THJ as a promising adjunct therapy for inflammation-driven coronary atherosclerosis. (Registration No. ChiCTR1900021772).
Indexed as
Identifiers
41838378What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.